Marvel Biosciences Corp. has completed a $500,000 private placement of unsecured convertible debentures, bearing 12% annual interest and maturing in December 2027, pending TSX Venture Exchange approval. The funds will support drug formulation, toxicology studies, and general working capital. Marvel is developing MB-204, a drug targeting neurological diseases like Parkinson's, autism, and Alzheimer's, with potential expansion into other neurodevelopmental disorders. This financing strengthens Marvel's capacity to advance its pharmaceutical research and development efforts.
The FTSE 100 index fell slightly, dragged down by mining stocks reacting to China's slower GDP growth of 4.3% in Q2, its weakest in three years. Despite this, oil prices remained steady amid US-Iran tensions. PayPal shares jumped over 14% following r...
The Goldman Sachs Future Tech Leaders Equity ETF (GTEK) has delivered a 48.9% return year-to-date, nearly doubling the 25% return of the Vanguard Information Technology ETF (VGT). Unlike VGT, which heavily invests in mega-cap tech giants like Nvidia,...
